You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 131 No. 6, June 1977 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Androgens, Estrogens, and the Ultimate Height in XO Gonadal Dysgenesis

Arye Lev-Ran, MD

Am J Dis Child. 1977;131(6):648-649.


Abstract

• We observed 40 patients with 45,X gonadal dysgenesis from the age of 13 to 15 years until the age of 18 to 21 years. The ultimate height of the 12 nontreated patients was 143.2 cm. Of 15 patients treated with nandrolone phenpropionate or methandrostenolone, the ultimate height was 143.3 cm, and of 13 patients treated with ethinyl estradiol, the height reached was 144.1 cm. The mean height of ten patients first seen at the age of 25 to 31 years was 140.1 cm. The mean height at any age was almost identical in all the groups. The growth velocity was somewhat accelerated by anabolic steroids and to a lesser extent, by estrogens only during the first year of therapy, and this did not influence the ultimate height. We saw no deleterious effects of the estrogens. In all the groups, there were patients who grew for some time at rates of up to 4 to 6 cm/yr. Therefore, long-term follow-up studies are needed for the evaluation of the effects of any treatment.

(Am J Dis Child 131:648-649, 1977)



Author Affiliations

From the Department of Internal Medicine "D", Beilinson Medical Center, Petah-Tikva, the Endocrine Laboratory of the Sick Fund, and Tel Aviv University Medical School, Tel Aviv, Israel.


Footnotes

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Disproportionate Growth of the Lower Extremities: A Major Determinant of Short Stature in Turner's Syndrome
Neufeld et al.
Arch Pediatr Adolesc Med 1978;132:296-298.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1977 American Medical Association. All Rights Reserved.